Advances in Alzheimer's and Parkinson's Disease : insights, progress, and perspectives

1. Clinical Features and Treatment of Dementia Associated With Parkinson’s Disease . 2. Neurogenetics in Parkinson’s Disease. Yoshikuni Mizuno and Nobutaka Hattori 3. Impaired DNA Repair Systems: Generation of Mitochondrial Dysfunction and Increased Sensitivity to Excitotoxicity Simona Francisconi, Mara Codenotti, Erminia Poli, Daniela Uberti, Giulia Ferrari-Toninelli, and Maurizio Memo 4. Current Problems and Strategies in Motor Rehabilitation for Parkinson’s Disease Giovanni Abbruzzese, Elisa Pelosin, and Roberta Marchese 5. Critical Acute Akinesia in Parkinson’s Disease Patients Concomitant with Additional Precipitating Factors Other Than Treatment Withdrawal: A Possible Lethal Complication Marco Onofrj and Astrid Thomas6. Biomarkers for Early Detection of Parkinson’s Disease: An Essential Florian Tribl and Peter Riederer 7. Neurotransmitter and Neurotrophic Factor- Isao Date, Tetsuro Shingo, and Takao Yasuhara 8. Novel Therapeutic Target in PD: Experimental Francesco Fornai vii 9. LRRK2 (Leucine-Rich Repeat Kinase 2) Gene on PARK8 Locus in Families with Parkinsonism Zbigniew K. Wszolek, Alexander Zimprich, Saskia Biskup, Ryan J. Uitti, Donald B. Calne, A. Jon Stoessl, Akiko Imamura, Matthew J. Farrer, Judith Miklossy, Thomas Meitinger, Thomas Gasser, Dennis W. Dickson, and Patrick L. McGeer 10. Microglia Activation and Gene Expression of Cytokines in Parkinson’s Disease . Makoto Sawada, Kazuhiro Imamura, and Toshiharu Nagatsu 11. Dissecting the Biochemical Pathways Mediated by Genes Implicated in Parkinson’s Disease: Induction of DJ-1 Expression in A30P a-Synuclein Mice Mark Frasier, Shanti Frausto, Daniel Lewicki, Lawrence Golbe, and Benjamin Wolozin 12. Neuroinflammation in Early Stages of Alzheimer’s Disease and Parkinson’s Disease .Margaret Fahnestock, S. Peng, D.J. Garzon, and Elliott J. Mufson Contents ix 29. Shift in the Balance of TRKA and ProNGF in Prodromal Alzheimer’s Disease . Elliott J.Mufson, ScottE.Counts, S. Peng, and Margaret Fahnestock 30. Neuroprotective Effects of Trophic Factors and Natural Products: Involvement of Multiple Extracellular Ste´phane Bastianetto, Wen-Hua Zheng, Yingshan Han, Lixia Gan, and Re´mi Quirion Lauren M. Billings and Frank M. LaFerla 32. Physiological Processing of the Cellular Prion Protein and bAPP: Enzymes and Regulation . Bruno Vincent, Moustapha Alfa Cisse, and Fre´de´ ric Checler 33. Expression of Wnt Receptors, Frizzled, in Rat Neuronal Cells . . Marcelo A. Chaco´ n,Marcela Columbres, and Nibaldo C. Inestrosa 34. Cell Models of Tauopathy J. Biernat, I. Khlistunova, Y-P. Wang,M. Pickhardt, M. von Bergen, Z. Gazova, Eckhart Mandelkow, and Eva-MarieMandelkow 35. Co-expression of FTDP-17 Human Tau and GSK-3b (or 31. Intraneuronal Ab and Alzheimer’s ) in Transgenic Mice: Induction of Tau Polymerization and Neurodegeneration . Jesu´ s Avila, Tobias Engel, Jose´ J. Lucas, Mar Pe´rez, Alicia Rubio, and Fe´ lix Herna´ ndez 36. Enhanced Activation of NF-kB Signaling by Apolipoprotein Gal Ophir, Liza Mizrahi, and Daniel M. Michaelson 37. Pleiotropic Effects of Apolipoprotein E in Dementia: Influence on Functional Genomics and Ramo´ n Cacabelos 38. Up-regulation of the a-Secretase Pathway .and Elz : bietaKojro 39. Frequency and Relation of Argyrophilic Grain Disease and Thorn- Shaped Astrocytes in Alzheimer’s Disease . Hirotake Uchikado,Yasuhiro Fujino,WenlangLin, andDennis Dickson 40. Cellular Membranes as Targets in Amyloid Oligomer Disease Pathogenesis . Erene W. Mina and Charles G. Glabe x Contents 41. Ganglioside-Dependent Generation of a Seed for Alzheimer’s Disease Amyloid Katsuhiko Yanagisawa 42. Evidence That Amyloid Pathology Progresses in a Neurotransmitter-Specific Manner . Karen F.S. Bell and A. Claudio Cuello 43. Rationale for Glutamatergic and Cholinergic Approaches for the Treatment of Alzheimer’s Disease Paul T. Francis and Sara L. Kirvell 44. Cortical Cholinergic Lesion Causes Ab Deposition: Cholinergic- Amyloid Fusion Hypothesis . Thomas Beach, Pamela Potter, Lucia Sue, Amanda Newell, Marissa Poston, Raquel Cisneros, Yoga Pandya, Abraham Fisher, Alex Roher, Lih-Fen Lue, and Douglas Walker 45. Expression of Acetylcholinesterase in Alzheimer’s Disease Brain: Role in Neuritic Dystrophy and Synaptic Scaling DavidH. Small, StevenPetratos, SharonUnabia, andDanutaMaksel 46. Role of b-Amyloid in the Pathophysiology of Alzheimer’s Disease and Cholinesterase Inhibition: Facing the Biological Complexity to Treat the Disease . Stefano Govoni, Michela Mazzucchelli, S. Carolina Lenzken, Emanuela Porrello, Cristina Lanni, and Marco Racchi 47. Dissociation Between the Potent b-Amyloid Protein Pathway Inhibition and Cholinergic Actions of the Alzheimer Drug Candidates Phenserine and Cymserine Nigel H. Greig, Tada Utsuki, Qian-sheng Yu, Harold W. Holloway, Tracyann Perry, David Tweedie, Tony Giordano, George M. Alley, De-Mao Chen, Mohammad A. Kamal, Jack T. Rogers, Kumar Sambamurti, and Debomoy K. Lahiri 48. Allosteric Potentiators of Neuronal Nicotinic Cholinergic Receptors: Potential Treatments for Neurodegenerative DisordersEmanuele Sher, Giovanna De Filippi, T. Baldwinson, Ruud Zwart, Kathy H. Pearson, Martin Lee, Louise Wallace, Gordon I.McPhie,Martine Keenan, Renee Emkey, Sean P. Hollinshead, Colin P.Dell, S. RichardBaker,Michael J. O’Neil, and Lisa